ASBP — Aspire Biopharma Holdings, Inc. Dilution Risk Tracker

Aspire Biopharma Holdings, Inc. (ASBP) carries a DilutionScore of 88/100, placing it in the Critical dilution risk tier — the highest category tracked by DilutionWatch. Companies at this level typically have active capital-raising programs, compressed cash runway, or a combination of dilution vectors that together represent meaningful downside risk to share count. As of July 14, 2026, this score reflects real-time data pulled directly from SEC EDGAR filings.

The most significant dilution vector for ASBP is its shelf registration capacity of $20.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely. DilutionWatch tracks 44.0M outstanding warrants for ASBP. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window.

DilutionWatch tracks over 25 SEC filing types for ASBP in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in ASBP's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for ASBP alongside comparable critical-risk stocks. Not financial advice — this analysis is for informational purposes only.